762 related articles for article (PubMed ID: 33761582)
21. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic.
Shao Y; Wu Y; Feng Y; Xu W; Xiong F; Zhang X
Front Med; 2022 Apr; 16(2):185-195. PubMed ID: 35226300
[TBL] [Abstract][Full Text] [Related]
22. Development of vaccines for SARS-CoV-2.
Ng WH; Liu X; Mahalingam S
F1000Res; 2020; 9():. PubMed ID: 32850116
[TBL] [Abstract][Full Text] [Related]
23. COVID-19 - Important considerations for developing and using a vaccine.
Rahman IU; Ali N; Ijaz F; Afzal A; Abd Allah EF
Hum Vaccin Immunother; 2021 Feb; 17(2):414-415. PubMed ID: 32693665
[TBL] [Abstract][Full Text] [Related]
24. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
Bennet BM; Wolf J; Laureano R; Sellers RS
Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
[TBL] [Abstract][Full Text] [Related]
25. From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?
Hanney SR; Wooding S; Sussex J; Grant J
Health Res Policy Syst; 2020 Jun; 18(1):61. PubMed ID: 32513202
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2: vaccines in the pandemic era.
Li DD; Li QH
Mil Med Res; 2021 Jan; 8(1):1. PubMed ID: 33402220
[TBL] [Abstract][Full Text] [Related]
27. Targets and strategies for vaccine development against SARS-CoV-2.
Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
[TBL] [Abstract][Full Text] [Related]
28. An overview on inactivated and live-attenuated SARS-CoV-2 vaccines.
Khoshnood S; Arshadi M; Akrami S; Koupaei M; Ghahramanpour H; Shariati A; Sadeghifard N; Heidary M
J Clin Lab Anal; 2022 May; 36(5):e24418. PubMed ID: 35421266
[TBL] [Abstract][Full Text] [Related]
29. A Possible Path towards Rapid Development of Live-Attenuated SARS-CoV-2 Vaccines: Plunging into the Natural Pool.
Todorov G; Uversky VN
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33066343
[TBL] [Abstract][Full Text] [Related]
30. A survey of mechanisms underlying current and potential COVID-19 vaccines.
Hebel C; Thomsen AR
APMIS; 2023 Feb; 131(2):37-60. PubMed ID: 36394112
[TBL] [Abstract][Full Text] [Related]
31. Adherence to Immunization: Rebuttal of Vaccine Hesitancy.
Etzioni-Friedman T; Etzioni A
Acta Haematol; 2021; 144(4):413-417. PubMed ID: 33202404
[TBL] [Abstract][Full Text] [Related]
32. COVID-19 vaccines: ethical framework concerning human challenge studies.
Calina D; Hartung T; Docea AO; Spandidos DA; Egorov AM; Shtilman MI; Carvalho F; Tsatsakis A
Daru; 2020 Dec; 28(2):807-812. PubMed ID: 32851596
[TBL] [Abstract][Full Text] [Related]
33. A comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines.
Abdolmaleki G; Taheri MA; Paridehpour S; Mohammadi NM; Tabatabaei YA; Mousavi T; Amin M
Daru; 2022 Dec; 30(2):379-406. PubMed ID: 36050585
[TBL] [Abstract][Full Text] [Related]
34. Status of COVID-19 vaccine development.
Taxt AM; Grødeland G; Lind A; Müller F
Tidsskr Nor Laegeforen; 2020 Sep; 140(13):. PubMed ID: 32998488
[TBL] [Abstract][Full Text] [Related]
35. Potential for elimination of SAR-CoV-2 through vaccination as inspired by elimination of multiple influenza viruses through natural pandemics or mass vaccination.
Chen JM; Sun YX; Chen JW
J Med Virol; 2020 Nov; 92(11):2453-2457. PubMed ID: 32525587
[TBL] [Abstract][Full Text] [Related]
36. COVID-19 vaccine development and a potential nanomaterial path forward.
Shin MD; Shukla S; Chung YH; Beiss V; Chan SK; Ortega-Rivera OA; Wirth DM; Chen A; Sack M; Pokorski JK; Steinmetz NF
Nat Nanotechnol; 2020 Aug; 15(8):646-655. PubMed ID: 32669664
[TBL] [Abstract][Full Text] [Related]
37. Unfolding the Determinants of COVID-19 Vaccine Acceptance in China.
Yin F; Wu Z; Xia X; Ji M; Wang Y; Hu Z
J Med Internet Res; 2021 Jan; 23(1):e26089. PubMed ID: 33400682
[TBL] [Abstract][Full Text] [Related]
38. A review of approved COVID-19 vaccines.
Jamkhande A; Khairnar MR; Gavali N; Patil Y; Kapare SS; Bhosale KP
Rocz Panstw Zakl Hig; 2021; 72(3):245-252. PubMed ID: 34553878
[TBL] [Abstract][Full Text] [Related]
39. Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs.
Malone B; Simovski B; Moliné C; Cheng J; Gheorghe M; Fontenelle H; Vardaxis I; Tennøe S; Malmberg JA; Stratford R; Clancy T
Sci Rep; 2020 Dec; 10(1):22375. PubMed ID: 33361777
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Strategies in the Fight against COVID-19: From Bench to Bedside.
Abadi B; Aarabi Jeshvaghani AH; Fathalipour H; Dehghan L; Rahimi Sirjani K; Forootanfar H
Iran J Med Sci; 2022 Nov; 47(6):517-532. PubMed ID: 36380976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
